Cardiovascular and gastrointestinal risks of NSAID pharmacotherapy: contradictions persist

Authors

  • L. A. Vozniuk National Pirogov Memorial Medical University, Vinnytsia
  • O. A. Yakovleva National Pirogov Memorial Medical University, Vinnytsia

Keywords:

NSAIDs, cardiovascular and gastorintestinal risks

Abstract

There is an underestimation by the majo ity of patients of the relevance of myocardial infarction and cardiovascular death risk in the background of NSAID pharmacotherapy. The results of the analysis should influence the awareness of patients when making individual decisions in favor of NSAIDs, particularly in case of chronic pain syndrome.

Downloads

Download data is not yet available.

References

Насонов Е.Л. Противовоспалительная терапия ревматических заболеваний. – М. : М-СИТИ, 1996.

Рациональная фармакотерапия ревматических заболеваний / Под ред. В. А. Насоновой, Е. Л. Насонова. – М., 2003.

Everts B., Wahrnborg P., Hedner T. // Clin. Rheumatol. – 2000. – V. 19. – Р. 331–334.

Andreotti F., Testa L., Biondi-Zoccai G. G., Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients // Eur Heart J. – 2006. – 27 : 519–526.

Bianchi M., Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, сelecoxib and rofecoxib in osteoarthritis of the knee // Drugs. – 2003. – 63 Suppl 1 : 37–46.

Bing B. J. Cyclooxygenase 2 inhibitors: Is there an association with coronary or renal events // Curr. Atherosclerosis. Report. – 2003. – 5 : 114–117.

Boers M. NSAIDs and selective COX 2 inhibitors: competition between gastroprotection and cardioprotection // Lancet 2001. – 357 : 1222–1223.

Bhatt et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use // JACC. – Bhatt et al. 1503, October 28, 2008. – Vol. 52, N 18 : 1502–1517.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti- inflammatory drugs: meta-analyses of individual participant data from randomised trials // Lancet, May 30 [Epub ehead of print].

Deeks J. J., Smith L. A., Bradley M. D. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systemic review of randomized controlled trials // BMJ. – 2002 (Sep 21). – 325(7365) : 619.

Hernandez-Diaz S., Garcia Rodriguez L. A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications // BMC Med. – 2006. – 4 : 22.

Lawrence R. C., Helmick C. G., Arnett F. C. et al. // Arthritis Rheum. – 1998. – V. 41. – Р. 778–779.

Lanas A., Serrano P., Bajador E., Fuentes J., Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs // Eur J Gastroenterol Hepatol. – 2003. – 15 : 173–178.

Moore R. A. // Rheumatology. – 2002. – V. 41 (Suppl.1). – Р. 7–15. 15. Singh G. // Amer. J. Ther. – 2000. – N 7. – Р. 115–121.

Simon L. S., Lipman A. G., Jacox A. K. et al. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis // Clinical Guideline No2: American Pain Society. – Glenview, IL. – 2002.

Taylor Nelson Sofres`Healthcare. – Script count., 2002.

Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs // Nature (New Biol.). – 1971. – 231 : 232–5.

Vane J. Towards a better aspirin // Nature. – 1994. – 367 : 215–216.

Florida Atlantic University. Most comprehensive analyses of NSAIDs and coxibs // Science Daily. – (2013) (May 31). – www. sciencedaily.com/releases/2013/05/130529190948.htm

Jeffrey S. NSAID CV-event risk high overall, but predictable in individuals, says analysis // HeartWire. – 2013 (May 30). – www. theheart.org/article/1545183.do

Taha A. S., Angerson W. J., Knill-Jones R. P., Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and antithrombotic drugs – a 6-year analysis and comparison with nonsteroidal anti-inflammatory drugs // Aliment Pharmacol Ther. – 2005. – 22 : 285–289.

Yusuf S., Mehta S. R., Xie C. et al. Effects of reviparin, a low-molecularweight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation // JAMA. – 2005. – 293 : 427–435.

Published

2016-12-01

How to Cite

1.
Vozniuk LA, Yakovleva OA. Cardiovascular and gastrointestinal risks of NSAID pharmacotherapy: contradictions persist. PMJUA [Internet]. 2016 Dec. 1 [cited 2022 Jun. 30];1(4):22-6. Available from: https://painmedicine.org.ua/index.php/pnmdcn/article/view/31